Original language | English |
---|---|
Pages (from-to) | e19 |
Journal | European Urology |
Volume | 76 |
Issue number | 1 |
DOIs | |
State | Published - Jul 2019 |
Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53
*Corresponding author for this work
Research output: Contribution to journal › Letter › peer-review